Matches in SemOpenAlex for { <https://semopenalex.org/work/W2271612713> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2271612713 endingPage "A599" @default.
- W2271612713 startingPage "A599" @default.
- W2271612713 abstract "Sodium-glucose transport protein 2 (SGLT-2) inhibitors demonstrate favorable efficacy profiles that include glycemic control and reductions in body weight but are associated with adverse events including ketoacidosis, urinary tract infections, candida vulvovaginitis, and hypoglycemia. This comparative safety and efficacy analysis is designed to compare relevant clinical endpoints in the prescribing information labels of available SGLT-2 inhibitors and identify the most prevalent and clinically significant outcomes which are crucial in the management of patients with type 2 diabetes (T2D). A multivariate analysis was undertaken using clinical endpoints from product information labels (n=3; canaglifozin, dapagliflozin, empagliflozin) of available SGLT-2 inhibitors. Compounds with 24- to 26-week, placebo-controlled endpoint data were analyzed. Efficacy endpoints included change from baseline in hemoglobin A1c (%) and body weight (kg). The safety endpoints included percentage of patients reporting adverse events, including urinary tract infections, female genital mycotic infections, and incidence of hypoglycemic events (%). No compound outperformed competitors in all predefined outcome measures after 24- to 26- weeks of treatment. Canagliflozin 300 mg + metformin reported the greatest reduction in body weight (-4.07 kg) and the greatest reduction in HbA1c (-1.06%). However, canagliflozin 300 mg + metformin (4.6%) reported the greatest incidence of hypoglycemia events and the greatest incidence of urinary tract infections (11.4%) after 26 weeks. Despite the robust efficacy profiles presented in this analysis, physicians should consider the potential adverse events associated with each SGLT-2 inhibitor before deciding on a treatment regimen. Diabetes treatment regimens are often highly individualized, and healthcare providers must weigh the benefits of any treatment with its attendant risks. Of special concern among SGLT-2 inhibitors is the recent US FDA warning of increased risk for diabetic ketoacidosis associated with these compounds." @default.
- W2271612713 created "2016-06-24" @default.
- W2271612713 creator A5000785350 @default.
- W2271612713 creator A5007451917 @default.
- W2271612713 creator A5017219752 @default.
- W2271612713 creator A5028629925 @default.
- W2271612713 date "2015-11-01" @default.
- W2271612713 modified "2023-10-18" @default.
- W2271612713 title "A Multivariate Safety and Efficacy Analysis of Prescribing Information for Next Generation SGLT-2 Inhibitors in Type 2 Diabetes Treatment" @default.
- W2271612713 doi "https://doi.org/10.1016/j.jval.2015.09.2051" @default.
- W2271612713 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26533363" @default.
- W2271612713 hasPublicationYear "2015" @default.
- W2271612713 type Work @default.
- W2271612713 sameAs 2271612713 @default.
- W2271612713 citedByCount "0" @default.
- W2271612713 crossrefType "journal-article" @default.
- W2271612713 hasAuthorship W2271612713A5000785350 @default.
- W2271612713 hasAuthorship W2271612713A5007451917 @default.
- W2271612713 hasAuthorship W2271612713A5017219752 @default.
- W2271612713 hasAuthorship W2271612713A5028629925 @default.
- W2271612713 hasBestOaLocation W22716127131 @default.
- W2271612713 hasConcept C126322002 @default.
- W2271612713 hasConcept C134018914 @default.
- W2271612713 hasConcept C197934379 @default.
- W2271612713 hasConcept C203092338 @default.
- W2271612713 hasConcept C2775887513 @default.
- W2271612713 hasConcept C2777180221 @default.
- W2271612713 hasConcept C2777422806 @default.
- W2271612713 hasConcept C2777451236 @default.
- W2271612713 hasConcept C2779306644 @default.
- W2271612713 hasConcept C2780323712 @default.
- W2271612713 hasConcept C2780473172 @default.
- W2271612713 hasConcept C2780668416 @default.
- W2271612713 hasConcept C535046627 @default.
- W2271612713 hasConcept C555293320 @default.
- W2271612713 hasConcept C71924100 @default.
- W2271612713 hasConcept C77411442 @default.
- W2271612713 hasConceptScore W2271612713C126322002 @default.
- W2271612713 hasConceptScore W2271612713C134018914 @default.
- W2271612713 hasConceptScore W2271612713C197934379 @default.
- W2271612713 hasConceptScore W2271612713C203092338 @default.
- W2271612713 hasConceptScore W2271612713C2775887513 @default.
- W2271612713 hasConceptScore W2271612713C2777180221 @default.
- W2271612713 hasConceptScore W2271612713C2777422806 @default.
- W2271612713 hasConceptScore W2271612713C2777451236 @default.
- W2271612713 hasConceptScore W2271612713C2779306644 @default.
- W2271612713 hasConceptScore W2271612713C2780323712 @default.
- W2271612713 hasConceptScore W2271612713C2780473172 @default.
- W2271612713 hasConceptScore W2271612713C2780668416 @default.
- W2271612713 hasConceptScore W2271612713C535046627 @default.
- W2271612713 hasConceptScore W2271612713C555293320 @default.
- W2271612713 hasConceptScore W2271612713C71924100 @default.
- W2271612713 hasConceptScore W2271612713C77411442 @default.
- W2271612713 hasIssue "7" @default.
- W2271612713 hasLocation W22716127131 @default.
- W2271612713 hasOpenAccess W2271612713 @default.
- W2271612713 hasPrimaryLocation W22716127131 @default.
- W2271612713 hasRelatedWork W1986052847 @default.
- W2271612713 hasRelatedWork W2171929509 @default.
- W2271612713 hasRelatedWork W2600856845 @default.
- W2271612713 hasRelatedWork W2736637978 @default.
- W2271612713 hasRelatedWork W2760191018 @default.
- W2271612713 hasRelatedWork W2807204184 @default.
- W2271612713 hasRelatedWork W3047245042 @default.
- W2271612713 hasRelatedWork W3098093747 @default.
- W2271612713 hasRelatedWork W4293550851 @default.
- W2271612713 hasRelatedWork W4381164657 @default.
- W2271612713 hasVolume "18" @default.
- W2271612713 isParatext "false" @default.
- W2271612713 isRetracted "false" @default.
- W2271612713 magId "2271612713" @default.
- W2271612713 workType "article" @default.